Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma is a research paper published in Journal of Clinical Oncology (2022). On theSindex it has a DataRank of 2.3. It has been cited 159 times, with 100 citing works in its 1-hop citation network.
Scored on demand from live citation data
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.761
From this paper's citation signal
Citation Network Contribution
1.6
From 100 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 100 citers.
National Institutes of Health
Grant: 1S10OD024973-01A1
Acquisition of High Performance Data and Computing Infrastructure to Advance Biomedical Research
National Institutes of Health
Grant: 5P30CA016056-40
Roswell Park Cancer Institute Cancer Center Support Grant
Fields of Study
Keywords
Sustainable Development Goals